Latest Synlait Milk (ASX:SM1) News

Synlait Milk has locked in a NZ$320 million refinancing package with a broad banking syndicate and replaced its $130 million shareholder loan, while shifting its financial year-end to December to match its major shareholder.

Synlait Milk is progressing a key refinancing of its senior bank facilities due June 2026 and plans to replace a $130 million shareholder loan with a two-year term facility. The company reports a preliminary $12 million net loss for the first four months of 2026 amid operational headwinds and asset sales.

Synlait Milk Limited has completed the sale of its North Island assets to Abbott for NZ$307 million, significantly reducing its bank debt and refocusing its operations on Canterbury.

Micro-caps stole the spotlight, led by a boardroom reset at Killi and a blockbuster cancer update from Amplia. Energy explorers and a few big raisings moved the other way, as traders sold hard into fresh dilution and weak price action.

Synlait confirms the imminent sale of its North Island assets to Abbott for NZ$307 million, aiming to reset its balance sheet amid a challenging half-year result. The company unveils a recovery roadmap focused on stabilising and scaling its core operations.

Synlait Milk Limited has reported a significant half-year loss driven by manufacturing setbacks and market pressures, alongside a strategic recovery roadmap focused on asset sales and operational overhaul.

Synlait Milk Limited has secured important amendments and waivers to its syndicated bank facilities, aligning its financial covenants with the upcoming sale of its North Island assets scheduled for April 2026.

Synlait Milk Limited reveals a challenging first half of 2026 with significant losses expected, as it pivots its operations around Canterbury following the upcoming sale of its North Island assets.

Synlait Milk Limited has temporarily expanded its banking facilities by NZ$50 million to manage ongoing cost impacts from earlier manufacturing challenges, while preparing to reduce debt through a major asset sale.

Abbott has received Overseas Investment Office approval to acquire Synlait Milk’s North Island manufacturing and warehouse facilities in a US$178 million deal, pending shareholder consent.

Synlait Milk Limited reports a modest profit turnaround in FY25 and announces a major sale of its North Island assets to Abbott, aiming to reduce debt and sharpen its focus on core operations.

Synlait has agreed to sell its North Island assets to global healthcare giant Abbott for approximately US$178 million, marking a strategic reset focused on debt reduction and operational simplification. The deal, expected to close by April 2026, positions Synlait to concentrate on its South Island operations and explore new growth avenues.